Focal Adhesion Kinase and p53 signal transduction pathways in cancer

Frontiers in Bioscience

Volumn 15, Issue 3, 2010, Pages 901-912

  Golubovskaya, Vita M ^a   Cance, William ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; Focal adhesion kinase; Inhibitors; MDM 2; P53; Protein interaction; Review; Small molecules; Survival; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; PROTEIN P53;

DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; PROMOTER REGION; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956626576     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3653     Document Type: Article

References (115)

1. M. D. Schaller, C. A. Borgman, B. S. Cobb, R. R. Vines, A. B. Reynolds and J. T. Parsons: pp125fak a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proceedings of the National Academy of Sciences of the United States of America, 89(11), 5192- 5196 (1992).
2. T. M. Weiner, E. T. Liu, R. J. Craven and W. G. Cance: Expression of focal adhesion kinase gene and invasive cancer. Lancet, 342(8878), 1024-1025 (1993). (Pubitemid 23314806)
3. L. V. Owens, L. Xu, R. J. Craven, G. A. Dent, T. M. Weiner, L. Kornberg, E. T. Liu and W. G. Cance: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Research, 55(13), 2752- 2755 (1995).
4. L. V. Owens, L. Xu, G. A. Dent, X. Yang, G. C. Sturge, R. J. Craven and W. G. Cance: Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Annals of Surgical Oncology, 3(1), 100-105 (1996). (Pubitemid 126729497)
5. W. G. Cance, J. E. Harris, M. V. Iacocca, E. Roche, X. Yang, J. Chang, S. Simkins and L. Xu: Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res, 6(6), 2417-2423. (2000). (Pubitemid 30399210)
6. P. L. Judson, X. He, W. G. Cance and L. Van Le: Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer, 86(8), 1551-1556 (1999). (Pubitemid 29489790)
7. A. L. Lark, C. A. Livasy, B. Calvo, L. Caskey, D. T. Moore, X. Yang and W. G. Cance: Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res, 9(1), 215-222 (2003). (Pubitemid 36109736)
8. H. M. Lightfoot, Jr., A. Lark, C. A. Livasy, D. T. Moore, D. Cowan, L. Dressler, R. J. Craven and W. G. Cance: Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat, 88(2), 109-116 (2004). (Pubitemid 39575569)
9. E. Kurenova, L.-H. Xu, X. Yang, A. S. Baldwin Jr., R. J. Craven, S. K. Hanks, Z.-g. Liu and W. G. Cance: Focal Adhesion Kinase Suppresses Apoptosis by Binding to the Death Domain of Receptor-Interacting Protein. Mol. Cell. Biol., 24(10), 4361-4371 (2004). (Pubitemid 41071006)
10. V. M. Golubovskaya, R. Finch and W. G. Cance: Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem, 280(26), 25008-25021 (2005). (Pubitemid 40934593)
11. V. M. Golubovskaya and W. G. Cance: Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol, 263, 103-153 (2007). (Pubitemid 47296394)
12. W. G. Cance and V. M. Golubovskaya: Focal Adhesion Kinase Versus p53: Apoptosis or Survival? Sci Signal, 1(20), pe22 (2008).
13. V. Golubovskaya, A. Kaur and W. Cance: Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites*1. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1678(2-3), 111-125 (2004). (Pubitemid 38626172)
14. V. M. Golubovskaya, R. Finch, F. Kweh, N. A. Massoll, M. Campbell-Thompson, M. R. Wallace and W. G. Cance: p53 regulates FAK expression in human tumor cells. Mol Carcinog, 47(5), 373-382 (2008). (Pubitemid 351614577)
15. F. T. Fiedorek, Jr. and E. S. Kay: Mapping of the focal adhesion kinase (Fadk) gene to mouse chromosome 15 and human chromosome 8. Mammalian Genome, 6(2), 123-126 (1995).
16. M. Agochiya, V. G. Brunton, D. W. Owens, E. K. Parkinson, C. Paraskeva, W. N. Keith and M. C. Frame: Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells Oncogene, 18(41), 5646-5653 (1999). (Pubitemid 29497599)
17. G. S. Whitney, P. Y. Chan, J. Blake, W. L. Cosand, M. G. Neubauer, A. Aruffo and S. B. Kanner: Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK. DNA & Cell Biology, 12(9), 823-830 (1993). (Pubitemid 24295358)
18. J. M. Corsi, E. Rouer, J. A. Girault and H. Enslen: Organization and post-transcriptional processing of focal adhesion kinase gene. BMC Genomics, 7, 198 (2006).
19. S. K. Hanks and T. R. Polte: Signaling through focal adhesion kinase. Bioessays, 19(2), 137-145 (1997). (Pubitemid 27114962)
20. M. D. Schaller, J. D. Hildebrand, J. D. Shannon, J. W. Fox, R. R. Vines and J. T. Parsons: Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2- dependent binding of pp60src. Molecular & Cellular Biology, 14(3), 1680-1688 (1994).
21. M. D. Schaller and J. T. Parsons: Focal adhesion kinase and associated proteins. Current Opinion in Cell Biology, 6(5), 705-710 (1994). (Pubitemid 24295304)
22. M. D. Schaller, C. A. Otey, J. D. Hildebrand and J. T. Parsons: Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. Journal of Cell Biology, 130(5), 1181-1187 (1995).
23. D. F. Ceccarelli, H. K. Song, F. Poy, M. D. Schaller and M. J. Eck: Crystal structure of the FERM domain of focal adhesion kinase. J Biol Chem, 281(1), 252-9 (2006). (Pubitemid 43671184)
24. L. A. Cooper, T. L. Shen and J. L. Guan: Regulation of focal adhesion kinase by its amino-terminal domain through an autoinhibitory interaction. Mol Cell Biol, 23(22), 8030-8041 (2003). (Pubitemid 37377496)
25. D. Lietha, X. Cai, D. F. Ceccarelli, Y. Li, M. D. Schaller and M. J. Eck: Structural basis for the autoinhibition of focal adhesion kinase. Cell, 129(6), 1177- 87 (2007). (Pubitemid 46891044)
26. G. W. McLean, N. O. Carragher, E. Avizienyte, J. Evans, V. G. Brunton and M. C. Frame: The role of focaladhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer, 5(7), 505-515 (2005). (Pubitemid 40942827)
27. M. D. Schaller, J. D. Hildebrand and J. T. Parsons: Complex formation with focal adhesion kinase: A mechanism to regulate activity and subcellular localization of Src kinases. Mol Biol Cell, 10(10), 3489-3505 (1999). (Pubitemid 29489577)
28. S. K. Hanks, L. Ryzhova, N. Y. Shin and J. Brabek: Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci, 8,d982-96 (2003). (Pubitemid 38943176)
29. M. B. Calalb, T. R. Polte and S. K. Hanks: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Molecular & Cellular Biology, 15(2), 954- 963 (1995).
30. J. Nowakowski, C. N. Cronin, D. E. McRee, M. W. Knuth, C. G. Nelson, N. P. Pavletich, J. Rogers, B. C. Sang, D. N. Scheibe, R. V. Swanson and D. A. Thompson: Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure, 10(12), 1659-1667 (2002). (Pubitemid 35452573)
31. J. T. Parsons: Focal adhesion kinase: the first ten years. J Cell Sci, 116(Pt 8), 1409-16 (2003). (Pubitemid 36527488)
32. T. C. Windham, N. U. Parikh, D. R. Siwak, J. M. Summy, D. J. McConkey, A. J. Kraker and G. E. Gallick: Src activation regulates anoikis in human colon tumor cell lines. Oncogene, 21(51), 7797-7807 (2002). (Pubitemid 35398837)
33. A. Richardson and J. T. Parsons: Signal transduction through integrins: a central role for focal adhesion kinase? Bioessays, 17(3), 229-236 (1995).
34. I. Hayashi, K. Vuori and R. C. Liddington: The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin. Nat Struct Biol, 9(2), 101-106 (2002). (Pubitemid 34132410)
35. K. C. Prutzman, G. Gao, M. L. King, V. V. Iyer, G. A. Mueller, M. D. Schaller and S. L. Campbell: The focal adhesion targeting domain of focal adhesion kinase contains a hinge region that modulates tyrosine 926 phosphorylation. Structure (Camb), 12(5), 881-891 (2004). (Pubitemid 38595776)
36. S. T. Arold, M. K. Hoellerer and M. E. Noble: The structural basis of localization and signaling by the focal adhesion targeting domain. Structure, 10(3), 319-327 (2002). (Pubitemid 34230620)
37. S. M. Frisch, K. Vuori, E. Ruoslahti and P. Y. Chan- Hui: Control of adhesion-dependent cell survival by focal adhesion kinase. Journal of Cell Biology, 134(3), 793-9 (1996). (Pubitemid 26269148)
38. S. M. Frisch and R. A. Screaton: Anoikis mechanisms. Curr Opin Cell Biol, 13(5), 555-562 (2001). (Pubitemid 32817013)
39. S. M. Frisch and E. Ruoslahti: Integrins and anoikis. Curr Opin Cell Biol, 9(5), 701-6 (1997). (Pubitemid 27424927)
40. S. M. Frisch: Evidence for a function of deathreceptor- related, death-domain-containing proteins in anoikis. Curr Biol, 9(18), 1047-1049 (1999). (Pubitemid 29456175)
41. L. H. Xu, L. V. Owens, G. C. Sturge, X. Yang, E. T. Liu, R. J. Craven and W. G. Cance: Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ, 7(4), 413-418 (1996). (Pubitemid 26362085)
42. C. S. Smith, V. M. Golubovskaya, E. Peck, L. H. Xu, B. P. Monia, X. Yang and W. G. Cance: Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res, 15(5), 357-362 (2005). (Pubitemid 41558945)
43. L. H. Xu, X. Yang, R. J. Craven and W. G. Cance: The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ, 9(12), 999-1005 (1998). (Pubitemid 29036194)
44. L.-h. Xu, X.-h. Yang, C. A. Bradham, D. A. Brenner, A. S. Baldwin, R. J. Craven and W. G. Cance: The focal adhesion kinase suppresses transformation-associated, anchorage-Independent apoptosis in human breast cancer cells. J. Biol. Chem., 275, 30597-30604 (2000).
45. V. Golubovskaya, L. Beviglia, L. H. Xu, H. S. Earp,3rd, R. Craven and W. Cance: Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem, 277(41), 38978-38987 (2002). (Pubitemid 35154764)
46. V. M. Golubovskaya, S. Gross, A. S. Kaur, R. I. Wilson, L. H. Xu, X. H. Yang and W. G. Cance: Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol Cancer Res, 1(10), 755-764 (2003). (Pubitemid 37025594)
47. L. Beviglia, V. Golubovskaya, L. Xu, X. Yang, R. J. Craven and W. G. Cance: Focal adhesion kinase Nterminus in breast carcinoma cells induces rounding, detachment and apoptosis. Biochem J, 373(Pt 1), 201-210 (2003). (Pubitemid 36819515)
48. B. van De Water, F. Houtepen, M. Huigsloot and I. B. Tijdens: Suppression of chemically induced apoptosis but not necrosis of renal proximal tubular epithelial (LLC-PK1) cells by focal adhesion kinase (FAK). Role of FAK in maintaining focal adhesion organization after acute renal cell injury. J Biol Chem, 276(39), 36183-36193 (2001).
49. V. Gabarra-Niecko, M. D. Schaller and J. M. Dunty: FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev, 22(4), 359- 74 (2003). (Pubitemid 36791892)
50. H. B. Park, V. Golubovskaya, L. Xu, X. Yang, J. W. Lee, S. Scully, 2nd, R. J. Craven and W. G. Cance: Activated Src increases adhesion, survival and alpha2- integrin expression in human breast cancer cells. Biochem J, 378(Pt 2), 559-567 (2004). (Pubitemid 38367245)
51. Y. Sonoda, Y. Matsumoto, M. Funakoshi, D. Yamamoto, S. K. Hanks and T. Kasahara: Anti-apoptotic Role of Focal Adhesion Kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of fak in a human leukemic cell line, HL-60. J Biol Chem, 275(21), 16309-16315 (2000). (Pubitemid 30366946)
52. T. Kasahara, E. Koguchi, M. Funakoshi, E. Aizu- Yokota and Y. Sonoda: Antiapoptotic action of focal adhesion kinase (FAK) against ionizing radiation. Antioxid Redox Signal, 4(3), 491-499 (2002). (Pubitemid 34753389)
53. H. B. Park, L.-H. Xu, X. Yang and W. G. Cance: Activated c-Src rescues cell rounding and loss of adhesion caused by attenuation of the focal adhesion kinase in human breast cancer cells. Surg. Forum, L, 346-7 (1999).
54. D. D. Schlaepfer and S. K. Mitra: Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev, 14(1), 92-101 (2004). (Pubitemid 38167483)
55. M. D. Schaller: Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta, 1540(1), 1-21 (2001). (Pubitemid 32710044)
56. C. R. Hauck, D. J. Sieg, D. A. Hsia, J. C. Loftus, W. A. Gaarde, B. P. Monia and D. D. Schlaepfer: Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res, 61(19), 7079-90 (2001). (Pubitemid 32946499)
57. D. Illc, Y. Furuta, S. Kanazawa, N. Takeda, K. Sobue, N. Nakatsuji, S. Nomura, J. Fujimoto, M. Okada, T. Yamamoto and et al.: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature, 377(6549), 539-544 (1995).
58. D. J. Sieg, C. R. Hauck and D. D. Schlaepfer: Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci, 112(Pt), 2677-2691 (1999). (Pubitemid 29429791)
59. J. D. Hildebrand, M. D. Schaller and J. T. Parsons: Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions. Journal of Cell Biology, 123(4), 993-1005 (1993). (Pubitemid 23333585)
60. R. W. Tilghman, J. K. Slack-Davis, N. Sergina, K. H. Martin, M. Iwanicki, E. D. Hershey, H. E. Beggs, L. F. Reichardt and J. T. Parsons: Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J Cell Sci, 118(Pt 12), 2613-2623 (2005). (Pubitemid 40932887)
61. M. G. Yeo, M. A. Partridge, E. J. Ezratty, Q. Shen, G. G. Gundersen and E. E. Marcantonio: Src SH2 arginine 175 is required for cell motility: specific focal adhesion kinase targeting and focal adhesion assembly function. Mol Cell Biol, 26(12), 4399-4409 (2006). (Pubitemid 43877562)
62. H. R. Reiske, S. C. Kao, L. A. Cary, J. L. Guan, J. F. Lai and H. C. Chen: Requirement of phosphatidylinositol 3-kinase in focal adhesion kinasepromoted cell migration. J Biol Chem, 274(18), 12361- 12366 (1999).
63. M. Tamura, J. Gu, K. Matsumoto, S. Aota, R. Parsons and K. M. Yamada: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280(5369), 1614-1617 (1998). (Pubitemid 28277707)
64. M. Tamura, J. Gu, E. H. Danen, T. Takino, S. Miyamoto and K. M. Yamada: PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem, 274(29), 20693-703 (1999).
65. N. Benlimame, Q. He, S. Jie, D. Xiao, Y. J. Xu, M. Loignon, D. D. Schlaepfer and M. A. Alaoui-Jamali: FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol, 171(3), 505-516 (2005). (Pubitemid 41586939)
66. M. Hanada, K. Tanaka, Y. Matsumoto, F. Nakatani, R. Sakimura, T. Matsunobu, X. Li, T. Okada, T. Nakamura, M. Takasaki and Y. Iwamoto: Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis. Clin Exp Metastasis, 22(6), 485-94 (2005). (Pubitemid 41750700)
67. A. L. Lark, C. A. Livasy, L. Dressler, D. T. Moore, R. C. Millikan, J. Geradts, M. Iacocca, D. Cowan, D. Little, R. J. Craven and W. Cance: High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol, 18(10), 1289-94 (2005). (Pubitemid 41348647)
68. X. Peng, H. Ueda, H. Zhou, T. Stokol, T. L. Shen, A. Alcaraz, T. Nagy, J. D. Vassalli and J. L. Guan: Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovasc Res, 64(3), 421-430 (2004). (Pubitemid 39505421)
69. L. J. Kornberg, L. C. Shaw, P. E. Spoerri, S. Caballero and M. B. Grant: Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis. Invest Ophthalmol Vis Sci, 45(12), 4463-4469 (2004). (Pubitemid 39564672)
70. S. K. Mitra, D. Mikolon, J. E. Molina, D. A. Hsia, D. A. Hanson, A. Chi, S. T. Lim, J. A. Bernard-Trifilo, D. Ilic, D. G. Stupack, D. A. Cheresh and D. D. Schlaepfer: Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 25, 5969- 5984(2006). (Pubitemid 44477291)
71. S. K. Mitra and D. D. Schlaepfer: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18, 516-523 (2006). (Pubitemid 44332916)
72. D. Ilic, E. A. Almeida, D. D. Schlaepfer, P. Dazin, S. Aizawa and C. H. Damsky: Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53- mediated apoptosis. J Cell Biol, 143(2), 547-560 (1998). (Pubitemid 28487870)
73. S. T. Lim, X. L. Chen, Y. Lim, D. A. Hanson, T. T. Vo, K. Howerton, N. Larocque, S. J. Fisher, D. D. Schlaepfer and D. Ilic: Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell, 29(1), 9-22 (2008).
74. A. J. Levine: p53, the cellular gatekeeper for growth and division. Cell, 88(3), 323-31 (1997). (Pubitemid 27131374)
75. G. Farmer, J. Bargonetti, H. Zhu, P. Friedman, R. Prywes and C. Prives: Wild-type p53 activates transcription in vitro. Nature, 358(6381), 83-86 (1992).
76. B. P. Bouchet, C. C. de Fromentel, A. Puisieux and C. M. Galmarini: p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol, 58(3), 190-207 (2006). (Pubitemid 43796080)
77. S. J. Baker, A. C. Preisinger, J. M. Jessup, C. Paraskeva, S. Markowitz, J. K. Willson, S. Hamilton and B. Vogelstein: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res, 50(23), 7717-7722 (1990).
78. D. Sidransky, T. Mikkelsen, K. Schwechheimer, M. L. Rosenblum, W. Cavanee and B. Vogelstein: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 355(6363), 846-847 (1992).
79. M. Hollstein, M. Hergenhahn, Q. Yang, H. Bartsch, Z. Q. Wang and P. Hainaut: New approaches to understanding p53 gene tumor mutation spectra. Mutat Res, 431(2), 199-209 (1999). (Pubitemid 30017791)
80. A. C. Willis and X. Chen: The promise and obstacle of p53 as a cancer therapeutic agent. Curr Mol Med, 2(4), 329- 345 (2002). (Pubitemid 35452883)
81. W. Wang, F. Rastinejad and W. S. El-Deiry: Restoring p53-dependent tumor suppression. Cancer Biol Ther, 2(4 Suppl 1), S55-63 (2003).
82. E. R. Fearon and B. Vogelstein: A genetic model for colorectal tumorigenesis. Cell, 61(5), 759-767 (1990).
83. A. J. Giaccia and M. B. Kastan: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev, 12(19), 2973-2983 (1998). (Pubitemid 28469299)
84. W. H. Hoffman, S. Biade, J. T. Zilfou, J. Chen and M. Murphy: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem, 277(5), 3247- 3257 (2002). (Pubitemid 34953189)
85. Y. Wu, J. W. Mehew, C. A. Heckman, M. Arcinas and L. M. Boxer: Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene, 20(2), 240-251 (2001). (Pubitemid 32150269)
86. W. R. Taylor and G. R. Stark: Regulation of the G2/M transition by p53. Oncogene, 20(15), 1803-1815 (2001). (Pubitemid 32458690)
87. K. Krause, M. Wasner, W. Reinhard, U. Haugwitz, C. L. Dohna, J. Mossner and K. Engeland: The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res, 28(22), 4410-4418 (2000).
88. J. I. Johnsen, O. N. Aurelio, Z. Kwaja, G. E. Jorgensen, N. S. Pellegata, R. Plattner, E. J. Stanbridge and J. F. Cajot: p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer, 88(5), 685-691 (2000).
89. M. Murphy, A. Hinman and A. J. Levine: Wild-type p53 negatively regulates the expression of a microtubuleassociated protein. Genes Dev, 10(23), 2971-2980 (1996). (Pubitemid 26412524)
90. V. Benoit, E. de Moraes, N. A. Dar, E. Taranchon, V. Bours, A. Hautefeuille, P. Taniere, A. Chariot, J. Y. Scoazec, C. V. de Moura Gallo, M. P. Merville and P. Hainaut: Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene, 25(42), 5708-5718 (2006). (Pubitemid 44435248)
91. C. L. Wei, Q. Wu, V. B. Vega, K. P. Chiu, P. Ng, T. Zhang, A. Shahab, H. C. Yong, Y. Fu, Z. Weng, J. Liu, X. D. Zhao, J. L. Chew, Y. L. Lee, V. A. Kuznetsov, W. K. Sung, L. D. Miller, B. Lim, E. T. Liu, Q. Yu, H. H. Ng and Y. Ruan: A global map of p53 transcription-factor binding sites in the human genome. Cell, 124(1), 207-219 (2006). (Pubitemid 43069320)
92. A. Stewart, C. Ham and I. Zachary: The focal adhesion kinase amino-terminal domain localises to nuclei and intercellular junctions in HEK 293 and MDCK cells independently of tyrosine 397 and the carboxy-terminal domain. Biochem Biophys Res Commun, 299(1), 62-73 (2002). (Pubitemid 35366036)
93. G. Jones and G. Stewart: Nuclear import of N-terminal FAK by activation of the FcepsilonRI receptor in RBL-2H3 cells. Biochem Biophys Res Commun, 314(1), 39-45 (2004). (Pubitemid 38058366)
94. M. Lobo and I. Zachary: Nuclear localization and apoptotic regulation of an amino-terminal domain focal adhesion kinase fragment in endothelial cells. Biochem Biophys Res Commun, 276(3), 1068-1074 (2000).
95. J. E. Chipuk and D. R. Green: Cytoplasmic p53: Bax and Forward. Cell Cycle, 3(4), 429-431 (2004). (Pubitemid 40278229)
96. V. Golubovskaya, R. Finch, M. Zheng, E. V. Kurenova and W. G. Cance: The 7 amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in interaction with FAK and is critical for p53 functioning. Biochem J, 411, 151-160, (2008). (Pubitemid 351482357)
97. E. K. Han, T. McGonigal, J. Wang, V. L. Giranda and Y. Luo: Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs. Anticancer Res, 24(6), 3899-3905 (2004). (Pubitemid 40468683)
98. H. S. Choi, Z. Wang, W. Richmond, X. He, K. Yang, T. Jiang, D. Karanewsky, X. J. Gu, V. Zhou, Y. Liu, J. Che, C. C. Lee, J. Caldwell, T. Kanazawa, I. Umemura, N. Matsuura, O. Ohmori, T. Honda, N. Gray and Y. He: Design and synthesis of 7H-pyrrolo[2, 3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorg Med Chem Lett, 16(10), 2689-2692 (2006).
99. Q. Shi, A. B. Hjelmeland, S. T. Keir, L. Song, S. Wickman, D. Jackson, O. Ohmori, D. D. Bigner, H. S. Friedman and J. N. Rich: A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007).
100. V. M. Golubovskaya, C. Virnig and W. G. Cance: TAE226-Induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 46(6), 488-96 (2007).
101. E. A. Beierle, A. Trujillo, A. Nagaram, V. M. Golubovskaya, W. G. Cance and E. V. Kurenova: TAE226 inhibits human neuroblastoma cell survival. Cancer Invest, 26(2), 145-151 (2008). (Pubitemid 351225463)
102. W. Liu, D. A. Bloom, W. G. Cance, E. V. Kurenova, V. M. Golubovskaya and S. N. Hochwald: Fak And Igf-Ir Interact To Provide Survival Signals In Human Pancreatic Adenocarcinoma Cells. Carcinogenesis 29(6), 1096-107 (2008). (Pubitemid 351958687)
103. J. K. Slack-Davis, K. H. Martin, R. W. Tilghman, M. Iwanicki, E. J. Ung, C. Autry, M. J. Luzzio, B. Cooper, J. C. Kath, W. G. Roberts and J. T. Parsons: Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem, 282(20), 14845-14852 (2007). (Pubitemid 47093369)
104. W. G. Roberts, E. Ung, P. Whalen, B. Cooper, C. Hulford, C. Autry, D. Richter, E. Emerson, J. Lin, 102. J. Kath, K. Coleman, L. Yao, L. Martinez-Alsina, M. Lorenzen, M. Berliner, M. Luzzio, N. Patel, E. Schmitt, S. LaGreca, J. Jani, M. Wessel, E. Marr, M. Griffor and F. Vajdos: Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562, 271. Cancer Res, 68(6), 1935-1944 (2008). (Pubitemid 351416580)
105. C. M. Bagi, G. W. Roberts and C. J. Andresen: Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer, 112(10), 2313-21 (2008). (Pubitemid 351628644)
106. L. T. Vassilev: p53 Activation by small molecules: application in oncology. J Med Chem, 48(14), 4491-4499 (2005). (Pubitemid 40993409)
107. S. A. Akhter, L. M. Luttrell, H. A. Rockman, G. Iaccarino, R. J. Lefkowitz and W. J. Koch: Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science, 280(5363), 574-577 (1998). (Pubitemid 28227758)
108. J. Aramburu, M. B. Yaffe, C. Lopez-Rodriguez, L. C. Cantley, P. G. Hogan and A. Rao: Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science, 285(5436), 2129-33 (1999). (Pubitemid 29451431)
109. M. J. May, F. D'Acquisto, L. A. Madge, J. Glockner, J. S. Pober and S. Ghosh: Selective inhibition of NFkappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science, 289(5484), 1550-1554 (2000).
110. E. van Rooij, P. A. Doevendans, C. C. de Theije, F. A. Babiker, J. D. Molkentin and L. J. de Windt: Requirement of nuclear factor of.
111. Y. N. Chen, S. K. Sharma, T. M. Ramsey, L. Jiang, M. S. Martin, K. Baker, P. D. Adams, K. W. Bair and W. G. Kaelin,Jr.: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A, 96(8), 4325-4329 (1999). (Pubitemid 29190335)
112. M. Aarts, Y. Liu, L. Liu, S. Besshoh, M. Arundine, J. W. Gurd, Y. T. Wang, M. W. Salter and M. Tymianski: Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science, 298(5594), 846-850 (2002). (Pubitemid 35231541)
113. S. T. Lim, N. L. Miller, J. O. Nam, X. L. Chen, Y. Lim and D. D. Schlaepfer: PYK2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem (2009) [Epub ahead of print].
114. V. M. Golubovskaya, C. Nyberg, M. Zheng, F. Kweh, A. Magis, D. Ostrov and W. G. Cance: A Small Molecule Inhibitor, 1, 2, 4, 5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth. J Med Chem 51(23), 7405-7416 (2008).
115. V. M. Golubovskaya, K. Conway-Dorsey, S. N. Edmiston, C. K. Tse, A. A. Lark, C. A. Livasy, D. Moore, R. C. Millikan and W. G. Cance: FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer, 125(7), 1735-1738 (2009).